Thymosin Alpha-1: What the Research Shows

Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026

Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide that the body makes; a synthetic version is sold outside the United States as Zadaxin and promoted online for “immune support”, Lyme disease, long COVID and chronic fatigue. Tested in people, in thousands of patients with hepatitis, sepsis, pancreatitis, cancer and COVID-19: side effects were few, and none of the three largest published placebo-controlled trials showed a benefit on its main outcome. The evidence stops short of the uses it is sold for: no trial in healthy people measured infections or any other health outcome, no study in patients was found for Lyme disease, long COVID or chronic fatigue syndrome, and no trial had an ageing outcome.

This review, part of our peptide library, sets out what was tested, in whom, and what wasn’t. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.

At a glance

FDA status
Not FDA-approved, and outside the FDA’s and HHS’s compounding policies.
Evidence in people
Thousands of trial patients; none of the three largest published placebo-controlled trials showed a benefit on its main outcome.
The claim you’ve heard
Immune support in healthy people: not tested. Healthy volunteers had only blood levels measured, for a week.
Doses tested in people
Usually 1.6 mg under the skin: twice weekly in hepatitis, once or twice daily in intensive care.
Sport
Not named on WADA’s 2026 or 2027 List. WADA says an unnamed peptide “may still be prohibited”.

What thymosin alpha-1 is

Thymosin alpha-1 is a chain of 28 amino acids, first isolated from calf thymus in 1977; in the body it is the first 28 amino acids of a larger protein, prothymosin alpha. Thymalfasin is the synthetic peptide, identical in sequence.

Three things share the name “thymosin”: thymosin alpha-1; thymosin beta-4, with its fragment TB-500; and thymosin fraction 5, the crude calf-thymus extract from which thymosin alpha-1 was isolated. They are different substances, and a study of one is never evidence for another.

Zadaxin is a finished medicine sold outside the United States by SciClone Pharmaceuticals: a freeze-dried single dose (1.6 mg) of chemically synthesized peptide. Italy’s and Hong Kong’s drug registers list it.

Where it stands with the FDA

Status checked: November 19, 2026.

In plain words: thymosin alpha-1 is not an FDA-approved medicine and is not on the FDA’s list of ingredients for compounding (making a medicine for one patient on a prescription). An FDA advisory committee voted against adding it in 2024, no rule has followed, and it is not in the draft compounding policy of HHS, the federal department the FDA belongs to.

As of November 19, 2026, thymosin alpha-1 (thymalfasin) is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. The FDA’s advisory committee voted against adding it on December 4, 2024 (4 in favor, 17 against, for each of its two forms; the vote is a recommendation, and the FDA has issued no rule adding it or excluding it), it is in none of the categories of the FDA’s interim policy for section 503A, the FDA lists it in Category 3, “Bulk Drug Substances Nominated Without Adequate Support”, of its policy for outsourcing facilities (substances the FDA says “are not eligible for the policy that applies to substances in category 1”), and it is not one of the six peptides named in HHS’s October 2026 draft interim policy; the FDA’s guidance says a drug compounded from a substance in this position “is not eligible for the exemptions in section 503A and may violate the FD&C Act.”

Section 503A is the compounding section of the federal Food, Drug, and Cosmetic Act (the FD&C Act). Category 3 describes a nomination made “with insufficient supporting information for FDA to evaluate”, not the FDA’s view of the evidence.

The FDA’s 2024 review proposed “not adding Ta1 (free base) or Ta1 acetate to the 503A Bulks List” (Ta1: its abbreviation; these are the two forms). At the committee meeting the FDA summed up: “we conclude there’s a lack of evidence to support the effectiveness of subQ administered Ta1 free base and Ta1 acetate for the evaluated uses. None of the clinical practice guidelines for U.S. health professionals recommend Ta1 free base or Ta1 acetate.” (subQ: under the skin.)

Safety, in the FDA’s words. The FDA says compounded drugs containing it “may pose significant risk for immunogenicity for certain routes of administration” and that “The safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.” The FDA’s 2024 review also says “In most clinical studies, Ta1 has been found to be well-tolerated” at 1 to 16 mg under the skin for up to 12 months, and concludes that its use “in compounding may raise safety concerns.” (Immunogenicity: an immune reaction to the peptide.) The 16 mg is the FDA’s own conversion of the largest single dose given into muscle to 14 cancer patients in a 1982 study, and the 12 months is the longest course at the usual 1.6 mg. The FDA’s document describes no study of 16 mg under the skin, and none of more than 6.4 mg given repeatedly.

HHS’s draft interim policy, announced October 30, 2026, names six peptides for which HHS said it “does not intend to take enforcement action” when its conditions are met. It is not FDA approval, and thymosin alpha-1 is not one of the six.

Warning letters. In 2020 the FDA and the Federal Trade Commission sent warning letters to two websites offering thymosin alpha-1 for COVID-19; one says “this product is an unapproved new drug sold in violation of section 505(a)”. Both turned on the COVID-19 claims.

Other countries. The FDA’s 2024 review says thymosin alpha-1 “is approved in Italy as an adjuvant to the influenza vaccine in immunocompromised subjects”, is approved in India for chronic hepatitis B and “is also approved in Hong Kong”, and that it “is licensed and marketed in many countries”; of the wider approvals claimed in the 2014 annual report of SciClone Pharmaceuticals, Zadaxin’s maker, the FDA wrote that it is “unable to independently verify these claims”. The FDA’s presentation of December 4, 2024 says “Ta1 is not approved in the United States, Japan, or Europe (except Italy)”. None of this changes its status in the United States: the FDA’s review says “FDA has approved no drug products containing Ta1.”

Sport. Thymosin alpha-1 is not named on WADA’s 2026 or 2027 Prohibited List; the only thymosin entry is “Thymosin-ß4 and its derivatives e.g. TB-500”, a different molecule. Class S0 prohibits “Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”; neither List says how WADA treats thymosin alpha-1. WADA’s note to the 2027 List says: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”

Claims you’ll see, and why sources disagree

Pages about thymosin alpha-1 disagree for three reasons.

  • Which trials get counted. Two pooled analyses of small sepsis trials found fewer deaths (risk ratios 0.59 and 0.68); the 1,106-patient trial designed to test that found no difference.
  • Trials in the sick stand in for the well. The evidence comes from people with hepatitis, sepsis or cancer; the uses sold online are “immune support” for healthy people and illnesses with no trial.
  • Approval abroad stands in for approval here. One seller’s page says “It’s FDA-approved in over 35 countries (though not the US)”. The FDA approves medicines for the United States only.

Where this review says “not tested”, that is not the same as “doesn’t work”. It cuts both ways: not shown to help, and not shown to be safe.

Claim Level of evidence Verdict
“Immune support” in healthy people; slower immune ageing None beyond blood levels in healthy volunteers Not tested. No trial in healthy people measured infections or any health outcome; none has an ageing outcome.
Treats Lyme disease, long COVID, chronic fatigue syndrome (ME/CFS) or mould illness None in patients (one lab study of blood cells, in long COVID) Not tested. The FDA found no clinical study in Lyme disease or ME/CFS.
“can alleviate symptoms in some autoimmune conditions” Tested in people once: 66 patients with immune thrombocytopenia, alongside a steroid Not tested on its own. With the steroid, complete response was 76.9% against 44.4% on the steroid alone (P < 0.05); randomization not stated.
“Curbs morbidity and mortality in sepsis” Tested in people Not shown: deaths at 28 days were 23.4% against 24.1% on placebo in the largest trial.
“It eradicates tumors” Animal studies; in people, tested only alongside other cancer treatment Not shown in people; the largest trial, in melanoma, found no significant survival gain.
“It is an effective treatment for Hepatitis B and C” Tested in people Not established. Hepatitis B: “very low” certainty (Cochrane, 2026). Hepatitis C: short-term measures improved in small trials with interferon (in one, of 109 patients, enzyme response 37.1% against 16.2%); no gain in cure rate in the three largest trials.
“Clinical studies have not revealed any adverse side effects” Tested in people Not established. Few events in trials, mostly at the injection site, but serious ones are on record (see Safety).

What the evidence consists of

The record is large: 98 PubMed records indexed as clinical trials and 67 registered studies, 43 with a site in China. Most we could read only as abstracts.

Tested in people

Study People Design What happened Funding or limits
TESTS (Wu, 2025), sepsis 1,106 adults, 22 centres in China Double-blind, placebo Deaths at 28 days: 23.4% against 24.1% (hazard ratio 0.97; 95% CI 0.76 to 1.24) Part-funded by Zadaxin’s maker; 17 withdrew before any dose
ETASS (Wu, 2013), severe sepsis 361 adults analysed of 367 randomised, six hospitals in China Single-blind, saline placebo Deaths at 28 days: 26.0% against 35.0% (relative risk 0.74; 0.54 to 1.02; P = 0.062, or 0.049 by log-rank test) Public funding; not confirmed by TESTS, from the same group
TRACE (Ke, 2022), severe pancreatitis 508 adults, 16 hospitals in China Double-blind, placebo Infected necrosis: 15.7% against 18.1% (difference −2.4%; −7.4 to 5.1) Part-funded by the maker, which supplied the drug
Ciancio, 2012, hepatitis C 552 adults, five European countries Double-blind, placebo, with peginterferon and ribavirin Cure (sustained viral response): 12.7% against 10.5% (P = 0.407); among completers, 41.0% against 26.3% (P = 0.048), not a randomized comparison Sponsored by the maker’s European partner; abstract only; by design, patients still virus-positive at 24 weeks stopped treatment
Two US trials, hepatitis C (begun 2002) More than 500 each Placebo-controlled phase 3, with peginterferon The sponsor reported no “statistically significant benefit” on either co-primary endpoint Known only from the maker’s 2006 annual report: no journal report, no numbers
Mutchnick, 1999, hepatitis B 97 adults Double-blind, placebo Complete response: 14% against 4% (P = 0.084) The only double-blind placebo-controlled hepatitis B trial of any size found
Wu X, 2018, hepatitis B cirrhosis 690 adults Open-label, with entecavir Liver decompensation, liver cancer or death “similar between two groups” The largest hepatitis B trial
Hepatitis B, pooled (Cochrane, 2026) 10 trials, 1,349 participants Review of randomized trials “may reduce all-cause mortality” (risk ratio 0.53; 0.29 to 0.96), but “we are not sure” “very low” certainty for every outcome but one
Chen, 2022, liver failure in hepatitis B 120 adults Open-label Transplant-free survival 75.0% against 53.4% (p = 0.030); new infections 32.1% against 58.6% (p = 0.005) Survival not significant in a second analysis
Maio, 2010, melanoma 488 adults Five groups, with chemotherapy Median survival 9.4 against 6.6 months (hazard ratio 0.80; 0.63 to 1.02) Sponsored by the maker’s European partner; responses not ordered by dose
Other cancer trials 42 (lung, 1985); 25 and 57 (liver) With other treatment Better survival in the lung trial, no phase 3 found; no significant difference in the 25; in the 57, recurrence no different, median survival 10.0 against 7.0 and 8.0 months (p = 0.002) Small or old
Chadwick, 2003, HIV 20 adults on antiretrovirals Open-label “no significant difference” in CD4 counts The FDA calls five HIV studies “inconclusive”
Vaccine response 90 older men (1989); 94 people on haemodialysis (2012) Placebo; vaccine alone Fourfold antibody rise in 69% against 52%; in 2012, higher levels at day 21 and a greater fall by day 42 Antibody levels. The one illness figure, in a 1989 meeting abstract of 337 older adults, “cannot be accurately evaluated” (the FDA)
COVID-19 49 in hospital (United States); 105 in hospital (India); 189 on haemodialysis, for prevention Open-label; double-blind, placebo; open-label No significant difference in recovery; deaths 11.1% against 38.5%, among India’s 40 severe patients only; infection in 5 of 91 against 7 of 98, no statistical test Small

What the intervals allow. The TESTS interval is compatible with about a quarter fewer deaths or a quarter more. Patients under 60 did worse on thymosin alpha-1 (hazard ratio 1.67; 1.04 to 2.67) and those 60 or over leaned the other way (0.81; 0.61 to 1.09); neither met the paper’s corrected threshold, so both are hypotheses. TRACE’s interval allows 7 points fewer cases or 5 more.

Pooled analyses. A 2025 analysis of 11 sepsis trials, TESTS among them, found fewer deaths overall (odds ratio 0.73; 0.59 to 0.90) but not in its high-quality or multicentre trials; its authors include the investigators of both sepsis trials. Pooled analyses of small trials also report benefits in pancreatitis, in lung and stomach cancer with chemotherapy (the lung analysis pooled it with another thymic peptide), and in flare-ups of chronic obstructive pulmonary disease; their authors call for better trials or rate the evidence low.

A 2024 narrative review reads the whole record more favourably: “Tα1 emerges as a well-tolerated and effective immune modulator”.

Reported in people

  • HIV. No change in CD4 counts in 20 treated patients (2024), no added rise in 12 (1996), and no effect on helper T-cell numbers in about ten men in 1986.
  • COVID-19. Six observational cohorts of 76 to 2,282 patients point both ways: lower mortality in one, a higher “non-recovery rate” in another. Sicker patients were more likely to be treated.

Animal studies

  • Tumours (mice). Growth was suppressed, but “the effect was not dose dependent, as all tested doses reduced tumor size by 45-50%”; the authors worked for or consulted to Zadaxin’s maker.
  • Toxicology. No published study; the FDA could not find the data behind the maker’s summary of no safety signals, and calls the nonclinical (animal and lab) data “too limited to inform safety considerations for potential clinical uses”.

Lab studies and how it is thought to work

The FDA’s staff wrote that “it is difficult to define the clinical relevance of the nonclinical pharmacological findings”. The proposal, from lab and animal studies, is that it activates dendritic cells (a type of immune cell). In people, an immune marker rose more with thymosin alpha-1 in the first sepsis trial; the larger trial found no difference in deaths, and the FDA wrote of the HIV studies that such measures “are not validated surrogate endpoints”.

Who produced the research

Zadaxin’s maker or its European partner funded, supported or sponsored several of the largest trials (TESTS, TRACE, the hepatitis C trials), which showed no benefit on their main outcomes, so the record is not one-sided. Where a larger trial followed a positive one (the 12-patient US hepatitis B pilot, the first Chinese sepsis trial, the pancreatitis pilot), it did not confirm it.

Dosing: what has been tested, what is used, and what the reasoning supports

This section reports and reasons; it recommends nothing. No trial has established a dose-response or compared schedules for a clinical outcome, so no dose can be called optimal.

Doses tested in people

The FDA’s summary: “The most common dose in clinical studies was 1.6 mg via SC administration” (SC: under the skin). The doses below were given under the skin unless stated.

  • Hepatitis: twice a week for six to twelve months, at 1.6 mg or 900 micrograms per square metre of body surface: 6 months in the placebo-controlled hepatitis B trial, 48 weeks with interferon in the European and both US hepatitis C trials, and 52 weeks in the 690-patient cirrhosis trial (dose not in its abstract).
  • Intensive care: 1.6 mg once or twice a day for one to two weeks. TESTS: every 12 hours for 7 days. ETASS: twice a day for 5 days, then once a day for 2. TRACE: every 12 hours for 7 days, then once a day for 7. The US hospital COVID-19 trial: daily for a week. A 24-patient pancreatitis pilot gave 3.2 mg twice a day, route not stated.
  • Daily for longer, in ill people only: 1.6 mg for 16 weeks after a haematopoietic transplant (a transplant of blood-forming cells; 14 people, and a meeting abstract of 30); 600 micrograms for 10 weeks in the 1986 HIV study; 1.6 mg five days a week for 24 weeks in 14 people with liver cancer.
  • Melanoma, and the highest amounts. The melanoma trial gave 1.6, 3.2 or 6.4 mg on days 8 to 11 and 15 to 18 of each 28-day cycle, for up to six cycles. People on haemodialysis had two doses of up to 6.4 mg; 14 people with advanced cancer, single doses into muscle of up to 9.6 mg per square metre; the Indian COVID-19 trial gave several injections a day, with no daily total stated. The maker’s label mentions volunteer studies of up to 16 mg and “no adverse reactions at doses up to 16 mg biw for 4 weeks” (biw: twice a week); those studies were not found.
  • Healthy volunteers: nine adults had 900 micrograms per square metre on six of seven days; only blood levels were measured.

No study in people was found of a nasal, oral or under-the-tongue product, of a flat amount below 600 micrograms, of use in children, or of any compounded or “research” product.

Doses in common use

These are amounts in circulation: practice that no trial set unless a study is named.

  • 1.6 mg under the skin twice a week is the dominant figure, and a label dose: a foreign regulator’s product information for Zadaxin states “1.6 mg (900 mcg/m 2 ) administered subcutaneously twice a week for 6 to 12 months” for chronic hepatitis B, as the hepatitis trials gave it.
  • The same figure, moved to healthy people. A telehealth seller’s dosing guide says “physicians commonly prescribe 1.6 mg subcutaneously twice per week for cycles of 8 to 12 weeks” for immune support and healthy ageing. No trial used such cycles in healthy people.
  • Small amounts daily or on weekdays. A telehealth product page states “0.2–0.4 mg per day, taken five days per week with two days off”; a telehealth blog, “1 mg every weekday, 5 mg per week”; a protocol-aggregator site, “1.5 mg subcutaneous in the morning, 5 days on / 2 days off, for 8-week cycles”. No human study was found behind any of them; the one sub-milligram daily regimen studied, in 1986, reported no effect on immune measures.
  • More for illness. The seller’s product page says “Some practitioners use higher doses (3.2 mg twice weekly) for acute infections or immune challenges”, an amount studied once, in the 20-person HIV trial that found no CD4 effect. A telehealth protocol guide lists “0.5 to 1.5 mg”, “Daily for 4 to 6 weeks, then taper” for ME/CFS and long COVID, conceding “no completed RCTs as of 2026”.
  • Nasal sprays and stronger solutions. The FDA’s staff found “3 mg and 10 mg nasal sprays” on US websites, and the withdrawn nomination proposed a 3 mg/mL injection. No study in people of a nasal product was found, and the FDA wrote that “the highest strength of Ta1 identified to date in clinical studies was 2 mg/mL.”

What the pharmacology supports, and what it doesn’t

  • Amount (measured in people). No dose-response has appeared: 0.8 mg and 1.6 mg, twice weekly for 24 weeks in 316 patients, gave “similar efficacy rates” in hepatitis B, and responses were not ordered across 1.6, 3.2 and 6.4 mg in melanoma. The FDA: “it is difficult to determine the minimal Ta1 dose required to induce a pharmacological response”. So reasoning can neither support nor rule out the smaller or larger amounts in circulation; the absence of a dose-response is itself a reason for caution.
  • Frequency (measured in people; then inferred). After a dose under the skin the blood level peaks at about 2 hours, has a half-life of about 2 hours and is back to baseline within 24 hours. So a twice-weekly schedule was never based on keeping the peptide in the blood: it assumes an effect on immune cells that outlasts the drug. That supports no schedule over another.
  • Route and form (measured in people for injection; then inferred). Every result above is from injection; a peptide sprayed into the nose or swallowed has no measured absorption in people, and that product information says it “should not be given intravenously”. The FDA wrote that “It is possible that a more concentrated solution of Ta1 could lead to aggregation, and therefore, increased immunogenicity potential” (aggregation: clumping), so a milligram of one product cannot be assumed to behave like a milligram of another.
  • Duration and monitoring (measured in people; convention; inferred). The longest courses studied ran about a year; cycles with breaks, and open-ended use, are convention without data. No blood test shows that it is “working” in a healthy person. By inference from the labels and the events on record, a prescriber would watch for an autoimmune flare, liver enzymes in anyone with hepatitis B, and allergic or injection-site reactions.

Nobody knows how long any effect on immune cells lasts after a dose, or what blood level a compounded, “research” or nasal product produces.

What common protocols get wrong

  • Trials in the sick, and only the favourable ones. The seller’s dosing guide rests its schedule for healthy people on studies in hepatitis, cancer, sepsis and vaccination, and cites the 2013 sepsis trial but not the 2025 one. A protocol-aggregator page lists the 2025 trial as “providing significant data on immune modulation in critical illness”; its main outcome showed no difference.
  • Studies misdescribed, or not found. A telehealth blog calls two single trials meta-analyses; a physician’s newsletter describes a 12-person ME/CFS study that is not in PubMed; a protocol guide cites “multiple Asian RCTs” in COVID-19, where one Indian and one US randomized trial were found.
  • Amounts and schedules no study used. One protocol-aggregator page’s own table gives a “Starting Dose” of “250 mcg” “3x weekly” and a “Maintenance Dose” of “500 mcg” “Weekly”, below any dose studied. Morning dosing, rest days, “8 weeks on, 8 weeks off” and “one month on, three months off” appear in no trial.

The dose is the prescriber’s decision for one patient.

Safety, and who should be most cautious

In the studies. People given thymosin alpha-1 in trials reported few side effects, mostly at the injection site, and the three large published placebo-controlled trials found no excess of adverse events (TESTS: any event in 66.4% against 67.6% on placebo; serious events in 26.8% against 29.3%). Cochrane’s hepatitis B review counted serious events in 54 of 534 people given it against 70 of 522 controls (low certainty). That record comes from sick people treated for defined periods, under supervision, with a pharmaceutical product. On record:

  • Pancreatitis (TRACE). Bleeding in 6.3% against 3.5% on placebo (P = 0.15); venous thrombosis in 6 patients against 5.
  • Hepatitis B. Of 316 patients, 22 had a transient flare of liver enzymes (11 at each dose) and 16 interrupted treatment; all recovered.
  • With interferon. Two patients had transient thyroid changes; the FDA’s one adverse-event report, through June 2024, is a man on both drugs hospitalized with anxiety and atrial fibrillation, causality “confounded by concurrent use of peginterferon”. The FDA notes that it does not receive every report, “especially for compounded products”.
  • After a haematopoietic transplant. Of six recipients of a half-matched (haploidentical) transplant, one “developed fatal immune hemolytic anemia” (the immune system destroying red blood cells) after thymosin alpha-1 and a donor lymphocyte infusion. The FDA: “It is unclear if Ta1 contributed to the severe and fatal immune reaction”; graft failure in one of six “raises concerns whether it is potentially related to Ta1 administration”, in data “difficult to interpret due to insufficient sample size and lack of details”.
  • Smaller reports. Nipple pain in over 10% of 14 people treated for liver cancer; one fever and two cases of mild nausea after single doses into muscle; in the dialysis trial, serious events in 28 of 91 against 26 of 98 and deaths in 3 against 7.
  • The maker’s label reports no “clinically significant adverse reactions attributable to thymosin alpha 1” among “over 2000 individuals”, and “rare instances of erythema, transient muscle atrophy, polyarthralgia combined with hand edema, and rash” (erythema: reddened skin; polyarthralgia: joint pains). The maker’s staff, as the FDA quotes them, estimate “>350,000 individuals exposed” since marketing.

Immunogenicity. The FDA’s concern (above) is a reasoned risk, untested either way: no study measuring antibodies against thymosin alpha-1 in treated people was found. Of peptides in general, the FDA writes that the consequences of an immune response “may range from antibody responses with no apparent clinical manifestations to life-threatening and catastrophic reactions”: a stated risk, not a reported event.

Theory, labelled as theory. On reasoning alone, the people with most reason for caution are those whose immune system is being held down on purpose (transplant recipients, people on immunosuppressants) and those with autoimmune disease: a drug meant to raise immune activity works against one meant to lower it. TESTS excluded the first two, and acute autoimmune disease.

Situation What is known Basis
Immunosuppressants; organ or haematopoietic transplant “it should be considered contraindicated in patients who are being deliberately immunosuppressed, such as organ transplant patients, unless the potential benefits of the therapy clearly outweigh the potential risks” A foreign regulator’s product information for Zadaxin
Autoimmune disease Not tested for safety; use “must be evaluated on a case-by-case basis” Italian label, as the FDA abstracts it
Pregnancy, breastfeeding “contraindicated during pregnancy and lactation”; “not known” whether it “can cause fetal harm” Italian label, as the FDA abstracts it; the maker’s label
Under 18 “Safety and effectiveness have not been established in patients below the age of 18 years.” The maker’s label
Hepatitis B or C Liver-enzyme flares can occur in hepatitis B. The FDA: use that delays an approved hepatitis B treatment “could have serious negative sequelae” The same product information; the FDA’s review
Other medicines Interactions “have not been fully evaluated”; caution with “other immunomodulating drugs” The maker’s label
Allergy to it Contraindicated after “hypersensitivity to thymosin alpha 1 or any component of the injection” The same product information
Cancer, now or in the past Cancer-causing potential has not been studied The maker’s label
Vaccines “Adding an immunomodulatory product such as Ta1 to any vaccine could pose additional, significant safety concerns” The FDA’s review

Product quality

  • The registered product is a single freeze-dried dose; the compounded and seller products described online are multi-dose, some at a higher strength.
  • The bulk substances. The FDA wrote in 2024 that data on “impurities, aggregates, bioburden, and bacterial endotoxins, were not found in publicly available scientific literature” for either form (bioburden: microbes; endotoxins: fever-causing bacterial fragments).
  • Recalls. Two firm-initiated recalls of compounded thymosin alpha-1 injections are on the FDA’s record: one begun in October 2026 for “Lack of Processing Controls”, one in 2020 for “Lack of Assurance of Sterility”.
  • Products sold online. No published laboratory analysis of any thymosin alpha-1 product was found. A 2026 preprint, not peer-reviewed, on fourteen other “research” peptides found that “41.6% to 71.1% of samples failed to meet basic quality criteria, and measurable endotoxin contamination was present in 15% of samples”; it did not test thymosin alpha-1.

What we make of it

This section is our reading of the evidence. It is a judgment, not a finding.

Thymosin alpha-1 has been studied in thousands of patients, and that study has not shown that it works. Its largest trials, in sepsis, pancreatitis and hepatitis C, showed no benefit on their main outcomes; the encouraging results come from small, open or early trials and pooled analyses of them, which larger trials, where run, did not confirm. For “immune support” in healthy people, Lyme disease, long COVID and chronic fatigue it is unproven and experimental: no trial has tested it.

A benefit is not ruled out: the hepatitis B data lean favourable at very low certainty, and the sepsis trial left open a benefit in older patients, a subgroup finding and so a hypothesis. But evidence in the critically ill is not evidence in the healthy.

What would have to be true: a blinded trial in the people it is sold to that shows fewer infections or better health, not only changed blood markers, and products that match the one studied.

For whom thymosin alpha-1 might ever be considered, after what, with what monitoring and when to stop are our Medical Director’s to state.

Peptide care at Rock Creek Wellness

Our peptide care starts with lab tests and a visit with one of our providers. The provider decides whether any peptide suits you, and which one; you don’t choose from a menu. How that care works is set out on our peptide therapy page, along with the other reviews in this library. What Peptide Care costs is on the same page.

So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.

What would change this review

  • A controlled trial in the people it is sold to. None of the 67 registered studies (eleven recruiting) is in Lyme disease, long COVID or chronic fatigue syndrome, or has an ageing or general “immune support” outcome; one phase 1 trial (NCT06821100, 75 planned, recruiting) gives older adults 4.8 mg once or twice before a COVID-19 booster, with safety as its main outcome.
  • The numbers from the two US hepatitis C trials, which only their sponsor has described.
  • An FDA rule adding thymosin alpha-1 to its compounding list or excluding it.

Common questions

Does thymosin alpha-1 boost the immune system?

Not in a way shown to matter to a well person’s health. Immune markers changed in some studies of sick patients, and some small trials in the seriously ill reported fewer infections; the largest trial with infection as its main outcome, in pancreatitis, did not, and no trial in healthy people measured infections.

Is thymosin alpha-1 the same as TB-500?

No. TB-500 is a fragment of thymosin beta-4, a different molecule with its own FDA and WADA entries; nothing known about one carries over to the other.

Is thymosin alpha-1 safe?

That is not established for the products sold here. In trials of the pharmaceutical product in sick patients, side effects were few, with the exceptions listed under Safety; no study in people of a compounded, “research” or nasal product was found.

Can a doctor prescribe thymosin alpha-1?

The federal sources we read give no yes or no about prescribers: their conditions attach to compounding and to the product. It is not FDA-approved, so a prescription would be for a compounded medicine, and the FDA’s guidance says a drug compounded from a substance in its position “is not eligible for the exemptions in section 503A and may violate the FD&C Act”.

How much thymosin alpha-1 do people take, and how often?

The trials most often gave 1.6 mg under the skin: twice a week for six to twelve months in hepatitis, or once or twice a day for one to two weeks in intensive care. Sellers’ pages carry the twice-weekly figure over to healthy people or state small daily amounts: practice no trial set. The dose is the prescriber’s decision for one patient.

Sources

Show all 72 sourcesHide sources
  1. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: Thymosin Alpha-1 (Ta1) – Related Bulk Drug Substances (Ta1 (free base) and Ta1 acetate). US Food and Drug Administration, 2024.
  2. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting December 4, 2024. US Food and Drug Administration, 2025.
  3. Pharmacy Compounding Advisory Committee, December 4, 2024: Transcript PM. US Food and Drug Administration, 2025.
  4. Pharmacy Compounding Advisory Committee, December 4, 2024: FDA Presentations PM. US Food and Drug Administration, 2024.
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. US Food and Drug Administration, 2026.
  6. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration, 2025.
  7. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (category list). US Food and Drug Administration, 2026.
  8. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B (category list). US Food and Drug Administration, 2025.
  9. Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act. US Food and Drug Administration, 2025.
  10. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability, 91 FR 68526, FR Doc. 2026-22192). Federal Register, 2026.
  11. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. US Department of Health and Human Services, 2026.
  12. Drug enforcement reports, product description “thymosin alpha” (recalls D-0145-2027 and D-0133-2021). US Food and Drug Administration (openFDA), 2026.
  13. Warning letter: Paradigm RE LLC, MARCS-CMS 612014. US Food and Drug Administration and Federal Trade Commission, 2020.
  14. Warning letter: Center for Wellness and Integrative Medicine, MARCS-CMS 608693. US Food and Drug Administration and Federal Trade Commission, 2020.
  15. AIFA, Zadaxin, AIC 028364026. Agenzia Italiana del Farmaco, read 2026.
  16. Hong Kong register, ZADAXIN FOR INJ. 1.6MG, record 155704. Hong Kong Drug Office, 2026.
  17. The 2026 Prohibited List. World Anti-Doping Agency, 2025.
  18. The 2027 Prohibited List. World Anti-Doping Agency, 2026.
  19. Summary of Major Modifications and Explanatory Notes, 2027 Prohibited List. World Anti-Doping Agency, 2026.
  20. ZADAXIN INJECTION [SIN07483P]. National Drug Formulary, Singapore, 2026.
  21. Zadaxin (Thymalfasin): side effects, uses, dosage. RxList (a US drug-reference site’s copy of the maker’s label text; not an FDA label), 2021.
  22. Form 10-K, annual report for the fiscal year ended December 31, 2006. SciClone Pharmaceuticals, Inc., filed with the US Securities and Exchange Commission, 2007.
  23. ClinicalTrials.gov: search for thymosin alpha-1, thymalfasin or Zadaxin as intervention (67 studies; records NCT02867267, NCT02473406, NCT00711620, NCT01178996, NCT00040027, NCT00039962, NCT00911443, NCT04428008, NCT04487444, NCT00001036 and NCT06821100 read). US National Library of Medicine, searched 2026.
  24. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proc Natl Acad Sci U S A, 1977.
  25. Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. J Biol Chem, 2003.
  26. Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers. Int J Clin Pharmacol Ther, 1999.
  27. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood, 2004.
  28. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ, 2025.
  29. BMJ 2025;389:r1098 (the journal’s correction to the TESTS report). BMJ, 2025.
  30. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit Care, 2013.
  31. Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Front Cell Infect Microbiol, 2025.
  32. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infect Dis, 2016.
  33. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis, 2015.
  34. Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial. Intensive Care Med, 2022.
  35. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study. Inflammation, 2011.
  36. Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. Front Immunol, 2025.
  37. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev, 2026.
  38. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat, 1999.
  39. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat, 2005.
  40. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opin Biol Ther, 2018.
  41. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology, 1991.
  42. Safety and efficacy of Thymosin α1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial. Hepatol Int, 2022.
  43. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?. J Viral Hepat, 2012.
  44. Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C. Ann N Y Acad Sci, 2007.
  45. Combination therapy with thymosin alpha1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology, 1998.
  46. A pilot study of the safety and efficacy of thymosin alpha 1 in augmenting immune reconstitution in HIV-infected patients with low CD4 counts taking highly active antiretroviral therapy. Clin Exp Immunol, 2003.
  47. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. J Infect Dis, 1996.
  48. Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV. BMC Infect Dis, 2024.
  49. Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects. J Biol Response Mod, 1986.
  50. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol, 2010.
  51. A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer. J Biol Response Mod, 1985.
  52. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int, 2009.
  53. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology, 2004.
  54. Clinical efficacy and safety of synthetic thymic peptides with chemotherapy for non-small cell lung cancer in China: A systematic review and meta-analysis of 27 randomized controlled trials following the PRISMA guidelines. Int Immunopharmacol, 2019.
  55. Efficacy and safety of thymosin α1 combined with chemotherapy for gastric cancer: a systematic review and meta-analysis of randomized controlled trials. Front Immunol, 2026.
  56. Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study. J Am Geriatr Soc, 1989.
  57. Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study. Vaccine, 2012.
  58. A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection. J Infect Dis, 2023.
  59. A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients. Indian J Crit Care Med, 2022.
  60. A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report. Int Immunopharmacol, 2023.
  61. Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clin Infect Dis, 2020.
  62. Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study. Front Immunol, 2021.
  63. Thymosin Alpha-1 Has no Beneficial Effect on Restoring CD4+ and CD8+ T Lymphocyte Counts in COVID-19 Patients. Front Immunol, 2021.
  64. The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study. Int Immunopharmacol, 2021.
  65. Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study. Int Immunopharmacol, 2020.
  66. Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching. Front Med (Lausanne), 2021.
  67. Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection. Int Immunopharmacol, 2023.
  68. [Combination therapy of thymosin alpha1 and high dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura]. Zhonghua Nei Ke Za Zhi, 2007.
  69. Thymosin alpha1 to harness immunity to pathogens after haploidentical hematopoietic transplantation. Ann N Y Acad Sci, 2010.
  70. Thymosin Alpha 1 Plus Routine Treatment for the Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. J Coll Physicians Surg Pak, 2024.
  71. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Altern Ther Health Med, 2024.
  72. Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprints.org (a preprint, not peer-reviewed), 2026.